The approval will help ensure the U.S. has a secure supply of the chemical agent for medical use, representing the first domestic supply in 30 years. The Nuclear Regulatory Commission is working with the FDA to license the RadioGenix System and enable the Tc-99m to be used for medical purposes.
“This radioisotope is vital to disease detection, yet healthcare professionals have faced challenges with adequate supply due to a complex supply chain that sometimes resulted in shortages,” said Janet Woodcock, MD, director of the FDA’s Center for Drug Evaluation and Research. “Today’s approval … marks the first domestic supply of Mo-99 — the source of Tc-99m — in 30 years, which will help to ensure more reliable, clean and secure access to this important imaging agent used in nuclear medicine.“
More articles on supply chain:
Indiana health systems face shortage of flu test kits: 3 things to know
Pentax recalls duodenoscope model: 3 things to know
Florida physician’s license restricted for allegedly masturbating during patient exam: 4 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
